Early indicators of primary brain tumours: a population-based study with 10 years' follow-up

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Early indicators of primary brain tumours : a population-based study with 10 years' follow-up. / Marku, M.; Rasmussen, B. K.; Dalton, S. O.; Johansen, C.; Hamerlik, P.; Andersen, K. K.; Meier, S. M.; Bidstrup, P. E.

In: European Journal of Neurology, Vol. 28, No. 1, 2021, p. 278-285.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Marku, M, Rasmussen, BK, Dalton, SO, Johansen, C, Hamerlik, P, Andersen, KK, Meier, SM & Bidstrup, PE 2021, 'Early indicators of primary brain tumours: a population-based study with 10 years' follow-up', European Journal of Neurology, vol. 28, no. 1, pp. 278-285. https://doi.org/10.1111/ene.14527

APA

Marku, M., Rasmussen, B. K., Dalton, S. O., Johansen, C., Hamerlik, P., Andersen, K. K., Meier, S. M., & Bidstrup, P. E. (2021). Early indicators of primary brain tumours: a population-based study with 10 years' follow-up. European Journal of Neurology, 28(1), 278-285. https://doi.org/10.1111/ene.14527

Vancouver

Marku M, Rasmussen BK, Dalton SO, Johansen C, Hamerlik P, Andersen KK et al. Early indicators of primary brain tumours: a population-based study with 10 years' follow-up. European Journal of Neurology. 2021;28(1):278-285. https://doi.org/10.1111/ene.14527

Author

Marku, M. ; Rasmussen, B. K. ; Dalton, S. O. ; Johansen, C. ; Hamerlik, P. ; Andersen, K. K. ; Meier, S. M. ; Bidstrup, P. E. / Early indicators of primary brain tumours : a population-based study with 10 years' follow-up. In: European Journal of Neurology. 2021 ; Vol. 28, No. 1. pp. 278-285.

Bibtex

@article{e1d939b148f04b73b1c2c0dba54b740e,
title = "Early indicators of primary brain tumours: a population-based study with 10 years' follow-up",
abstract = "Background and purposeTo improve diagnoses of primary brain tumours, knowledge about early indicators is needed. Nationwide Danish health registries were used to conduct a population‐based case–control study including all persons diagnosed with a primary brain tumour between 2005 and 2014 in Denmark.MethodsAll 5135 adults diagnosed with a primary brain tumour in the Danish Cancer Registry were matched to 19 572 general population comparisons from the Danish Civil Registration System. Conditional logistic regression analyses were applied to estimate age‐ and multivariable‐adjusted odds ratios (ORs) for the occurrence of a primary brain tumour up to 10 years after hospital diagnoses or prescription of medications related to nervous system diseases and mental and behavioural disorders.ResultsIncreased odds for primary brain tumour after nervous system diseases and mental and behavioural disorders manifested up to 10 years before tumour diagnosis were found. Increased odds were seen especially for hospital contacts for inflammatory nervous system diseases [OR 11.3; 95% confidence interval (CI) 6.5–19.7], epilepsy (OR 9.0; 95% CI 7.6–10.7) and antiepileptic medications (OR 3.6; 95% CI 3.2–4.0), whilst antidementia medications provided a strong, protective association for primary brain tumours (OR 0.5; 95% CI 0.3–0.8).ConclusionsSub‐groups of patients diagnosed with or being prescribed certain medications targeting nervous system diseases and mental and behavioural disorders may be at increased risk of being diagnosed with a primary brain tumour. Further studies should disentangle the potential underlying common pathogenetic pathways. The results are important for the development of systematic clinical approaches to ensure early diagnosis of primary brain tumours.",
keywords = "adult, case-control study, oncology, primary brain tumour, risk factors",
author = "M. Marku and Rasmussen, {B. K.} and Dalton, {S. O.} and C. Johansen and P. Hamerlik and Andersen, {K. K.} and Meier, {S. M.} and Bidstrup, {P. E.}",
year = "2021",
doi = "10.1111/ene.14527",
language = "English",
volume = "28",
pages = "278--285",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Early indicators of primary brain tumours

T2 - a population-based study with 10 years' follow-up

AU - Marku, M.

AU - Rasmussen, B. K.

AU - Dalton, S. O.

AU - Johansen, C.

AU - Hamerlik, P.

AU - Andersen, K. K.

AU - Meier, S. M.

AU - Bidstrup, P. E.

PY - 2021

Y1 - 2021

N2 - Background and purposeTo improve diagnoses of primary brain tumours, knowledge about early indicators is needed. Nationwide Danish health registries were used to conduct a population‐based case–control study including all persons diagnosed with a primary brain tumour between 2005 and 2014 in Denmark.MethodsAll 5135 adults diagnosed with a primary brain tumour in the Danish Cancer Registry were matched to 19 572 general population comparisons from the Danish Civil Registration System. Conditional logistic regression analyses were applied to estimate age‐ and multivariable‐adjusted odds ratios (ORs) for the occurrence of a primary brain tumour up to 10 years after hospital diagnoses or prescription of medications related to nervous system diseases and mental and behavioural disorders.ResultsIncreased odds for primary brain tumour after nervous system diseases and mental and behavioural disorders manifested up to 10 years before tumour diagnosis were found. Increased odds were seen especially for hospital contacts for inflammatory nervous system diseases [OR 11.3; 95% confidence interval (CI) 6.5–19.7], epilepsy (OR 9.0; 95% CI 7.6–10.7) and antiepileptic medications (OR 3.6; 95% CI 3.2–4.0), whilst antidementia medications provided a strong, protective association for primary brain tumours (OR 0.5; 95% CI 0.3–0.8).ConclusionsSub‐groups of patients diagnosed with or being prescribed certain medications targeting nervous system diseases and mental and behavioural disorders may be at increased risk of being diagnosed with a primary brain tumour. Further studies should disentangle the potential underlying common pathogenetic pathways. The results are important for the development of systematic clinical approaches to ensure early diagnosis of primary brain tumours.

AB - Background and purposeTo improve diagnoses of primary brain tumours, knowledge about early indicators is needed. Nationwide Danish health registries were used to conduct a population‐based case–control study including all persons diagnosed with a primary brain tumour between 2005 and 2014 in Denmark.MethodsAll 5135 adults diagnosed with a primary brain tumour in the Danish Cancer Registry were matched to 19 572 general population comparisons from the Danish Civil Registration System. Conditional logistic regression analyses were applied to estimate age‐ and multivariable‐adjusted odds ratios (ORs) for the occurrence of a primary brain tumour up to 10 years after hospital diagnoses or prescription of medications related to nervous system diseases and mental and behavioural disorders.ResultsIncreased odds for primary brain tumour after nervous system diseases and mental and behavioural disorders manifested up to 10 years before tumour diagnosis were found. Increased odds were seen especially for hospital contacts for inflammatory nervous system diseases [OR 11.3; 95% confidence interval (CI) 6.5–19.7], epilepsy (OR 9.0; 95% CI 7.6–10.7) and antiepileptic medications (OR 3.6; 95% CI 3.2–4.0), whilst antidementia medications provided a strong, protective association for primary brain tumours (OR 0.5; 95% CI 0.3–0.8).ConclusionsSub‐groups of patients diagnosed with or being prescribed certain medications targeting nervous system diseases and mental and behavioural disorders may be at increased risk of being diagnosed with a primary brain tumour. Further studies should disentangle the potential underlying common pathogenetic pathways. The results are important for the development of systematic clinical approaches to ensure early diagnosis of primary brain tumours.

KW - adult

KW - case-control study

KW - oncology

KW - primary brain tumour

KW - risk factors

U2 - 10.1111/ene.14527

DO - 10.1111/ene.14527

M3 - Journal article

C2 - 32916012

VL - 28

SP - 278

EP - 285

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 1

ER -

ID: 250604401